Merck & Co., Inc: Dyslipidemias trials

The registry lists 26 Dyslipidemias studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 9Phase 2 6Phase 3 9No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)TerminatedNCT03960541Phase 2Results posted
• Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)TerminatedNCT01414166Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)TerminatedNCT01294683Phase 3Results posted
• Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)TerminatedNCT01274559Phase 3Results posted
• Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)CompletedNCT01245738Results posted
• A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)CompletedNCT00961636Phase 3Results posted
• MK0524A Bioequivalence Study (0524A-059)CompletedNCT00944645Phase 1Results posted
• MK0524B Bioequivalence Study (0524B-070)CompletedNCT00943124Phase 1Results posted
• Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)CompletedNCT00935259Phase 1Results posted
• Fenofibrate Bioequivalence Study (0767-031)CompletedNCT00928694Phase 1Results posted
• A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)CompletedNCT00847197Phase 2Results posted
• MK-0524B Lipid Study (MK-0524B-063)CompletedNCT00479882Phase 3Results posted
• Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)CompletedNCT00479388Phase 3Results posted
• A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)CompletedNCT01760460Phase 3
• Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)CompletedNCT01122667Phase 1
• Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)CompletedNCT01114490Phase 1
• A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)CompletedNCT01104519Phase 1
• A Study of the Kinetics of a 13C-Cholesterol Infusate in Healthy Male Subjects (0000-108)(COMPLETED)CompletedNCT01101763
• Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)CompletedNCT01071291Phase 1
• The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)CompletedNCT00990808Phase 1
• A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)CompletedNCT00977288Phase 2
• MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)TerminatedNCT00703690Phase 2
• Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)WithdrawnNCT00664287Phase 3
• Dyslipidemia in Type 2 Diabetes (0767-034)TerminatedNCT00547274Phase 3
• MK0354 Clinical Efficacy and Tolerability Study (0354-004)TerminatedNCT00337415Phase 2
• An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)CompletedNCT00111891Phase 2